Investing.com - Novavax (NASDAQ: NVAX) reported third quarter EPS of $-0.760, $0.07 better than the analyst estimate of $-0.830. Revenue for the quarter came in at $85M versus the consensus estimate of $65.8M.
Guidance
Novavax sees FY 2024 revenue of $650.000M-$700.000M versus the analyst consensus of $761.500M.
Novavax's stock price closed at $9.01. It is down -30.480% in the last 3 months and up 43.700% in the last 12 months.
Novavax saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Novavax's stock price’s past reactions to earnings here.
According to InvestingPro, Novavax's Financial Health score is "good performance".
Check out Novavax's recent earnings performance, and Novavax's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar